patients (OR 1.77; 95%CI 1.09-2.85; p¼0.02). Estimated 5-yr RFS, CSS, and OS in patients <70 versus 70 was 70% vs 62% (p¼0.14), 84% vs 77% (p¼0.06), and 74% vs 54% (p<0.01). On multivariable Cox regression analyses, age 70 was not independently associated with RFS (HR 1.10; 95% CI 0.79-1.52; p¼0.57) or CSS (HR 1.22; 95% CI 0.82-1.82; p¼0.32), but remained associated with decreased OS (HR 1.91; 95% CI 1.50-2.45; p<0.01). Moreover, among all patients and as stratified by age, pathologic upstaging was associated with worse RFS, CSS, and OS on both multivariable Cox proportional hazards regression and in competing risk (of non-cancer death) models (Table) .
INTRODUCTION AND OBJECTIVES:
The Vitamin D Receptor (VDR) gene has been found to regulate the expression of cathelicidin, an antimicrobial peptide which represent a significant portion of the body's immune response against mycobacterium tuberculosis. VDR is also associated with macrophage phagocytosis, which is a key driver of the cell-mediated immunological response stimulated by BacillusCalmette Guerin (BCG). Various VDR single nucleotide polymorphisms (SNP) have been found to be associated with increased susceptibility to pulmonary tuberculosis. Hence, we hypothesize that this group of patients may similarly be unable to mount an immune response during the administration of intravesical BCG. In this study, we evaluated the predictive role of 3 VDR SNPs in the context of Asian patients with non-muscle invasive bladder cancer (NMIBC) recurrence and BCG immunotherapy outcome.
METHODS: Peripheral blood DNA was prospectively obtained from 140 evaluable EORTC intermediate to high risk NMIBC patients, who underwent post-transurethral resection intravesical regimes of BCG or BCG with interferon alpha. 3 VDR SNPs commonly implicated in susceptibility to tuberculosis infections were evaluated using high resolution melt (HRM) analysis. Results were confirm with sequence analysis. Kaplan-Meier together with Log-Rank test and Cox regression methods were used to analyze the data. RESULTS: Genotype frequencies were similar between the NMIBC patients and controls in accordance to the Hardy Weinberg equilibrium. Mean follow-up time was 91.9 months. Overall mean time to recurrence and progression was 25.8 months and 47.0 months respectively. Kaplan-Meier analysis indicate that individuals carrying the VDR genotype rs1544410 A/G were significantly associated with lower recurrence-free survival rates after BCG therapy (p¼0.007). The VDR rs1544410 "A" allele frequency was found to be higher in patients with bladder cancer recurrences (p¼0.01). 100.0% of patients with the VDR genotype rs731236 C/C had carcinoma in situ of the bladder, compared to 20.5% of the patients with the genotype T/T and 12.5% of the patients with the genotype T/C (?2 (2)¼ 8.31, p¼0.016). No association of VDR genotypes with progression-free survival was found.
CONCLUSIONS: Our findings suggest that polymorphisms in the VDR gene correlate with response to BCG therapy in NMIBC patients and further work should be performed to evaluate their utility as predictive markers of response to BCG immunotherapy. 
The Combat BRS system is a novel hyperthermia delivering device which allows temperature controlled delivery and re-circulation of HM via a urethral catheter using an external heat source. HIVEC I and II are two randomized control trials to determine if HM is superior to MMC alone in intermediate risk non-muscle invasive bladder cancer (NMIBC). We report safety and tolerability outcomes comparing the two treatment arms.
METHODS: HIVEC I and II are multi-centre, open-labeled randomized controlled trials recruiting patients from 25 Spanish and UK centers. The HIVEC I randomizes patients to either MMC, HM for 30 mins and HM for 60 mins (HM 60). Patients receive 4 once weekly treatments followed by 3 one monthly treatments. HIVEC II randomizes patients to MMC or HM 60 where both treatment arms receive 6 weekly treatments. Both trials use 40 mg MMC diluted in either 50 ml (HIVEC I) or 40 ml (HIVEC II) of sterile water. We compared all HIVEC I and II patients who were randomized to MMC (n¼154) or HM 60 (n¼153). HM was delivered by heating MMC to 43 C. Adverse events (AE) were reviewed by the independent data monitoring committee. HIVEC I and II were registered with EudraCT (2013-002628-18) and ISRCTN (23639415) respectively. RESULTS: 307 patients were included for analysis. 88.9% and 94.8% of HM and MMC patients respectively completed inductive therapy. Reasons for stopping therapy in 17 HM patients include: MMC allergy (n¼ 11), urinary symptoms (n¼2), pain (n¼1), haematuria (n¼1), pneumonia (n¼1) and in 8 MMC patients include: MMC allergy (n¼7) and angina (n¼1). AE which led to early termination of treatment were Grade II. There was no significant difference in patients with AE between HM (n¼78, 51%) and MMC (n¼66, 42.9%) (p¼0.154). Most AE were Grade ¼II (HM: 97.7%, MMC: 98.5%). There was no Grade >III related AE. There was no difference in pain (HM: 13.1% vs MMC: 8.4, p¼0.190) , dysuria (HM: 5.2% vs MMC: 6.5%, p¼0.617), urgency (HM: 11.8% vs MMC: 3.9%, p¼0.067), incontinence (HM: 3.3% vs MMC: 0.6%, p¼0.097) and rash/ allergic reaction (HM: 7.8% vs MMC: 5.2%, p¼0.327). HM treated patients were significantly more likely to develop urinary frequency (HM: 15.0% vs MMC: 5.8%, p¼0.008), haematuria (HM: 11.8% vs MMC: 3.9%, p¼0.010) and bladder spasm (HM: 6.5% vs MMC: 0.6%, p¼0.006).
CONCLUSIONS: HM delivered using the Combat BRS system is safe and well tolerated. The majority of AE in the HM arm were low grade with urinary frequency and haematuria more common in HM in comparison to MMC treated patients. HM represents a safe and well tolerated intravesical treatment for NMIBC.
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